FDAsafety guidance83% confidence
Drug Trials Snapshots: PALSONIFY
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (lung cancer) as Janssen.
Regulatory Analysis
PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.
Supporting Context
- Therapeutic area
- Oncology · NSCLC
- Sub-indication
- Lung Cancer
Related signal: Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials